Compare AbbVie Inc (ABBV) vs GraniteShares 2x Long COIN Daily ETF (CONL) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

CONL trades at $5.62, up 4.07% today but remains a highly volatile leveraged ETF tracking Coinbase stock. Technical indicators show bearish momentum with mixed oscillators, while financial ratios are unavailable for this derivative product. Recent news highlights extreme volatility, with the fund losing 67% year-to-date as daily reset leverage magnifies Coinbase price swings.

The outlook remains speculative with potential for explosive gains if Coinbase rallies, but structural risks from daily leverage reset create significant volatility decay. Investors face amplified exposure to cryptocurrency market sentiment and Coinbase performance without traditional company fundamentals to anchor valuation.